SAN DIEGO, June 9, 2011 (GLOBE NEWSWIRE) -- Harbor BioSciences, Inc. (OTCBB:HRBR) today announced that it has signed an umbrella generic drugs distribution agreement with China Institute of Pharmaceutical Industry (CIPI). In December, Harbor BioSciences, a biopharmaceutical development company, licensed the research and development and commercialization rights for three of its products exclusively in the People’s Republic of China and Hong Kong, to CIPI, a vertically integrated drug development organization that is jointly owned by the Chinese government and the Sinopharm Group.
